ANIX - NASDAQ
Anixa Biosciences, Inc.
$2.52
-6.7%Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. It has a collaboration agreement with MolGenie GmbH to discover and develop anti-viral drug candidates against COVID-19. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.
At a Glance
Live SnapshotSEC Filings
ANIX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | March 11, 2026 | March 10, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | March 09, 2026 | January 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 09, 2026 | February 09, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | January 28, 2026 | January 28, 2026 | 2026 | |
10-K 10-K 2025 FY FY | January 12, 2026 | October 31, 2025 | 2025 | |
8-K 8-K 2025 N/A | December 12, 2025 | December 11, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | September 10, 2025 | July 31, 2025 | 2025 | |
S-3 S-3 N/A | September 10, 2025 | September 10, 2025 | ||
10-Q 10-Q 2025 Q2 Q2 | May 28, 2025 | April 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | March 21, 2025 | March 20, 2025 | 2025 |
Understanding SEC Filings
Essential regulatory documents for investors
SEC filings are mandatory documents that publicly traded companies must submit to the Securities and Exchange Commission. These reports provide critical insights into a company's financial health, operations, risks, and strategic direction. For investors conducting due diligence, these filings are the most authoritative source of company information.
Annual Report
Comprehensive annual financial report filed within 60-90 days of fiscal year-end. Includes audited financial statements, management discussion & analysis (MD&A), risk factors, and detailed business operations. The most thorough financial disclosure of the year.
Quarterly Report
Unaudited quarterly financial report filed within 40-45 days after each of the first three fiscal quarters. Provides updates on financial position, results of operations, and significant events. Essential for tracking quarterly performance trends.
Current Report
Event-driven filing for material events that shareholders should know about, filed within 4 business days. Includes acquisitions, executive changes, bankruptcy, earnings releases, and other significant developments. Critical for staying informed about breaking news.
Proxy Statement
Definitive proxy statement sent to shareholders before annual meetings. Contains executive compensation details, board member information, voting matters, and corporate governance policies. Key for understanding management incentives and board composition.
Registration Statement
Initial registration for securities offerings, including IPOs. Provides detailed company history, business model, financial statements, risk factors, and use of proceeds. Essential for evaluating new investment opportunities and understanding company fundamentals.
Foreign Annual Report
Annual report for foreign private issuers, equivalent to Form 10-K for non-U.S. companies. Filed within 4-6 months of fiscal year-end. Contains audited financials, business description, and regulatory disclosures adapted for international companies.
Why SEC Filings Matter
- Regulatory Accuracy: Filings are subject to SEC review and legal penalties for misstatements, ensuring high data quality
- Management Insights: MD&A sections reveal management's perspective on trends, challenges, and future outlook
- Risk Assessment: Detailed risk factor disclosures help investors understand potential threats to business operations
- Competitive Analysis: Business descriptions and segment data enable comparison with industry peers
- Historical Context: Years of filings provide trend analysis and context for current performance
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.